This study is designed to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.

To evaluate the safety and efficacy of an oral investigational medication in people with moderately to severely active ulcerative colitis.

This study is testing a medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn’s Disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn's disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating UC.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is. This is compared to a placebo in people living with moderately to severely active UC.

This study is testing an investigational medicine called afimkibart.  Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC)  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active UC.

The study objective is to assess the efficacy, safety, and pharmacokinetics of an investigational drug in pediatric subjects from 2 to < 18 years of age with moderately to severely active Crohn’s disease (CD) who have had inadequate responses, loss of response, or intolerance to corticosteroids, immunosuppressants, and/or biologics, or in whom use of those therapies is medically contraindicated.

The objective of this study is to assess the PK, efficacy, and safety of the investigational drug in pediatric patients with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to aminosalicylates, oral locally acting corticosteroids, systemic corticosteroids, immunosuppressants, and/or biologic therapies.

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe Crohn’s Disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.

The primary objective of this study is to evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active UC. The primary endpoint is remission by central read Mayo score following 44 weeks in the maintenance phase. Remission is defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.